[{"data":1,"prerenderedAt":152},["ShallowReactive",2],{"drug-dichlorphenamide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":66,"warnings":76,"renal":84,"monitoring":85,"interactions":86,"review":87,"examples":90,"iran":96,"usApproval":103,"links":109,"populations":117},"dichlorphenamide",1,{"fa":7,"en":8},"دی‌کلرفنامید","Dichlorphenamide","nervous-system",{"fa":11,"en":12},"مهارکننده کربنیک انیدراز","Carbonic anhydrase inhibitor",[14],{"name":15,"market":16},"Keveyis","US",[18,19],"keveyis","دی کلرفنامید",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet (scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",true,[16],[32],{"source":33,"section":34},"fda-keveyis","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"limits":51,"notes":55},"pp","periodic-paralysis",{"fa":40,"en":41},"فلج دوره‌ای اولیه هیپو\u002Fهیپرکالمیک — شروع ۵۰ mg یک یا دو بار در روز (حداکثر ۲۰۰ mg\u002Fروز)","Primary hypo\u002Fhyperkalaemic periodic paralysis — start 50 mg once or twice daily (max 200 mg\u002Fday)",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"2.1",{"maxPerDay":52,"refs":53},200,[54],{"source":33,"section":50},[56],{"text":57,"refs":60},{"fa":58,"en":59},"تنظیم هفتگی بر اساس پاسخ؛ حداقل ۵۰ و حداکثر ۲۰۰ mg\u002Fروز. پاسخ پس از ۲ ماه ارزیابی شود. پتاسیم و بی‌کربنات پایه و دوره‌ای.","Adjust weekly by response; min 50 and max 200 mg\u002Fday. Evaluate response after 2 months. Baseline and periodic potassium and bicarbonate.",[61,62,64],{"source":33,"section":50},{"source":33,"section":63},"2.2",{"source":33,"section":65},"2.3",[67],{"id":68,"severity":69,"text":70,"refs":73},"ci","block",{"fa":71,"en":72},"حساسیت به دی‌کلرفنامید یا سولفونامیدها؛ آسپرین دوز بالا همزمان؛ بیماری شدید ریوی؛ نارسایی کبد.","Hypersensitivity to dichlorphenamide or other sulfonamides; concomitant high-dose aspirin; severe pulmonary disease; hepatic insufficiency.",[74],{"source":33,"section":75},"4",[77],{"text":78,"refs":81},{"fa":79,"en":80},"واکنش‌های تهدیدکننده حیات سولفونامیدی (قطع با اولین بثورات)؛ هیپوکالمی؛ اسیدوز متابولیک؛ زمین خوردن.","Life-threatening sulfonamide reactions (stop at first rash); hypokalaemia; metabolic acidosis; falls.",[82],{"source":33,"section":83},"5",[],[],[],{"status":88,"reviewer":89,"date":89},"unverified",null,[91],{"regimen":37,"formulation":22,"input":92,"expect":95},{"ageYears":93,"weightKg":94},30,70,{"perDose":27,"tabletsPerDoseRounded":5},{"status":97,"refs":98},"not-found",[99],{"source":100,"section":101,"url":102},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Dichlorphenamide",{"kind":104,"refs":105,"id":108},"NDA",[106],{"source":33,"section":107},"SPL approval \u002F marketing category","NDA011366",[110,113],{"kind":111,"url":112,"label":108},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=011366",{"kind":114,"url":115,"label":116},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d30a87b9-90fb-35b2-e053-2995a90aea2c","FDA Keveyis",{"pregnancy":118,"lactation":127,"pediatric":135,"geriatric":144},{"level":119,"text":120,"quote":123,"refs":124},"caution",{"fa":121,"en":122},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of KEVEYIS in pregnant women.",[125],{"source":33,"section":126},"8.1",{"level":119,"text":128,"quote":131,"refs":132},{"fa":129,"en":130},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of dichlorphenamide in human milk, the effects on the breastfed infant, or the effects on milk production.",[133],{"source":33,"section":134},"8.2",{"level":136,"text":137,"quote":140,"refs":141},"not-established",{"fa":138,"en":139},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of KEVEYIS in pediatric patients have not been established.",[142],{"source":33,"section":143},"8.4",{"level":119,"text":145,"quote":148,"refs":149},{"fa":146,"en":147},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The risk of falls and of metabolic acidosis are greater in elderly patients [see Warnings and Precautions (5.4 , 5.5) ] ​.",[150],{"source":33,"section":151},"8.5",1792156173914]